Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Rhea-AI Summary

Blueprint Medicines (NASDAQ: BPMC) has scheduled its first quarter 2025 financial results announcement and corporate update for Thursday, May 1, 2025, at 8:00 a.m. ET. The company will host a live conference call and webcast for this presentation.

Participants can access the conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with conference ID 082088. A webcast will be available in the Investors & Media section of Blueprint Medicines' website, remaining accessible for 30 days after the call.

News Market Reaction

+1.82%

1 alert

+1.82% News Effect

On the day this news was published, BPMC gained 1.82%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update.

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT^®/AYVAKYT^® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2025-financial-results-on-thursday-may-1-2025-302437712.html

SOURCE Blueprint Medicines Corporation

FAQ

When will Blueprint Medicines (BPMC) report Q1 2025 earnings?

Blueprint Medicines will report Q1 2025 earnings on Thursday, May 1, 2025, at 8:00 a.m. ET.

How can investors access Blueprint Medicines' (BPMC) Q1 2025 earnings call?

Investors can dial 833-470-1428 (domestic) or 404-975-4839 (international) with ID 082088, or access the webcast at Blueprint Medicines' investor relations website.

How long will Blueprint Medicines' (BPMC) Q1 2025 earnings webcast be available?

The earnings webcast will be available for 30 days following the call on Blueprint Medicines' website.

Where can I find Blueprint Medicines' (BPMC) Q1 2025 earnings webcast?

The webcast will be available under 'Events and Presentations' in the Investors & Media section at http://ir.blueprintmedicines.com/